X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Lead Product(s): Dendritic Cell Immunotherapy
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2023
Details:
DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Lead Product(s): Dendritic Cell Immunotherapy
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Lead Product(s): Dendritic Cell Immunotherapy
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor.
Lead Product(s): Dendritic Cell Immunotherapy
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Substantial percentage of patients who received DCVax-L (Dendritic Cell Immunotherapy) in the prior Phase I/II clinical trials have continued in a “long tail” of survival far beyond even the 3 year median survival.
Lead Product(s): Dendritic Cell Immunotherapy
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM).
Lead Product(s): DCVax-L
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Flaskworks has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax®.
Lead Product(s): DCVax-L
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Flaskworks
Deal Size: $4.3 million Upfront Cash: $1.6 million
Deal Type: Acquisition September 01, 2020
Details:
Remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytics firms.
Lead Product(s): DCVax-L
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
Data collection from all of the clinical trial sites for the Company's Phase 3 trial of DCVax®-L for Glioblastoma brain cancer (the "Trial") has been completed and all of the sites have signed off on the locking of their data.
Lead Product(s): DCVax-L
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
The Company reported that the final data collection process for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer has been progressing steadily despite ongoing difficulties due to coronavirus-related limitations on operations and restrictions at trial sites.
Lead Product(s): DCVax-L
Therapeutic Area: Oncology Product Name: DCVax-L
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
